Q3 2025 AngioDynamics Inc Earnings Call Transcript
Key Points
- AngioDynamics Inc (ANGO) reported a strong third quarter with total worldwide revenue of $72 million, representing a growth of over 9% year over year.
- The MedTech segment experienced significant growth, increasing by 22%, driven by strong performance across all platforms.
- The Auryon platform continued its robust performance, growing approximately 17% over the prior year, marking 15 consecutive quarters of double-digit growth.
- Mechanical thrombectomy products, AlphaVac and AngioVac, showed impressive growth, with combined revenue increasing by approximately 47% year over year.
- The NanoKnife segment saw a 16% growth in probe revenue, supported by an expanded FDA indication for prostate tissue ablation, enhancing its market potential.
- Despite improvements, AngioDynamics Inc (ANGO) reported an adjusted EPS loss of $0.08 per share, although this was an improvement from a loss of $0.16 per share in the previous year.
- The Med Device segment showed minimal growth, with revenue increasing by only 1% over the previous year.
- Capital sales for NanoKnife were lower than expected, declining 21.6% during the quarter.
- The company is still navigating complex reimbursement processes for the NanoKnife system, with significant reliance on future CPT code implementation.
- AngioDynamics Inc (ANGO) utilized $13.2 million in operating cash during the quarter, impacting its cash flow, although it expects to generate cash in the fourth quarter.
Good morning and welcome to the AngioDynamics fiscal year 20,253 quarter earnings call. (Operator Instructions) As a reminder, this conference call is being recorded.
The news released detailing AngioDynamics fiscal 2025 third quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet at the investor section of the company's website at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings, and gross margins for fiscal year 2025, as well as trends that may continue. Management encourages you to review the company's past and future filings with the SEC, including without limitation, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
